Literature DB >> 18046089

Is heart failure more prevalent in patients with peripheral arterial disease? A meta-analysis.

Rishi G Anand1, Hector O Ventura, Mandeep R Mehra.   

Abstract

Because risk factors for heart failure (HF) cluster in persons with peripheral artery disease (PAD), the authors conducted a meta-analysis to examine the prevalence of HF in individuals with PAD. MEDLINE searches were performed to review all PAD clinical trials (1966-2003). Expected control population prevalence rates for HF were derived from the National Health and Nutrition Examination Survey (NHANES) database. In total, 11,304 patients were evaluated. The average age of the patients was 67+/-5 years. The prevalence of HF in patients with PAD was 7.9% (range, 5.3%-13.9%) compared with an expected prevalence of 4.1%(range, 3.7-4.5%). The relative risk for increased HF prevalence among those with PAD was 1.9 (range, 1.35-3.10; P<.001). Thirteen (range, 7-19) PAD patients needed to be screened to detect 1 case of HF. The presence of PAD is associated with a 2-fold increase in the prevalence of HF. The use of PAD as a risk marker for underlying HF may enhance the effectiveness of screening criteria for HF detection.

Entities:  

Mesh:

Year:  2007        PMID: 18046089     DOI: 10.1111/j.1527-5299.2007.07344.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  8 in total

Review 1.  Peripheral arterial disease and chronic heart failure: a dangerous mix.

Authors:  Sally C Inglis; Adriana Hermis; Sajad Shehab; Phillip J Newton; Sara Lal; Patricia M Davidson
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

2.  Update on peripheral artery disease: Epidemiology and evidence-based facts.

Authors:  Jun Shu; Gaetano Santulli
Journal:  Atherosclerosis       Date:  2018-05-22       Impact factor: 5.162

3.  Prognostic value of ankle brachial index for future incident heart failure in patients without previous heart failure: data from the impressive predictive value of ankle brachial index for clinical long term outcome in patients with cardiovascular disease examined by ABI study.

Authors:  Hitoshi Nishimura; Takashi Miura; Masatoshi Minamisawa; Yasushi Ueki; Naoyuki Abe; Naoto Hashizume; Tomoaki Mochidome; Mikiko Harada; Kunihiko Shimizu; Wataru Shoin; Koji Yoshie; Yasutaka Oguchi; Soichiro Ebisawa; Hirohiko Motoki; Atsushi Izawa; Jun Koyama; Uichi Ikeda
Journal:  Heart Vessels       Date:  2016-07-13       Impact factor: 2.037

4.  Serum N-terminal pro-B-type natriuretic peptide levels are associated with functional capacity in patients with peripheral arterial disease.

Authors:  Jin Fan; Hayan Jouni; Mahyar Khaleghi; Kent R Bailey; Iftikhar J Kullo
Journal:  Angiology       Date:  2011-11-17       Impact factor: 3.619

5.  Evaluation of the consequences associated with diffuse vascular disease history in patients diagnosed with peripheral arterial disease: estimates from Saskatchewan health data.

Authors:  Kristen Migliaccio-Walle; Michael Stokes; Irina Proskorovsky; Dan Popovici-Toma; Wissam El-Hadi
Journal:  BMC Cardiovasc Disord       Date:  2010-09-02       Impact factor: 2.298

6.  The heart matters in diabetes: 10-Year outcomes of peripheral artery disease.

Authors:  Thomas Mueller; Franz Hinterreiter; Werner Poelz; Meinhard Haltmayer; Benjamin Dieplinger
Journal:  SAGE Open Med       Date:  2017-11-13

7.  Two-Step Geometry Design Method, Numerical Simulations and Experimental Studies of Bioresorbable Stents.

Authors:  Natalia Molęda; Grzegorz Kokot; Wacław Kuś; Michał Sobota; Jakub Włodarczyk; Mateusz Stojko
Journal:  Materials (Basel)       Date:  2022-03-24       Impact factor: 3.623

8.  Impact of Modified H2FPEF Score on Chronic Limb-Threatening Ischemia in Patients With Lower Extremity Artery Disease Who Underwent Endovascular Therapy.

Authors:  Taku Shikama; Yoichiro Otaki; Tetsu Watanabe; Hiroki Takahashi; Tasuku Kurokawa; Harutoshi Tamura; Shigehiko Kato; Satoshi Nishiyama; Takanori Arimoto; Masafumi Watanabe
Journal:  Circ Rep       Date:  2022-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.